Lung cancer is characterized by the highest incidence of solid tumor-related brain metastases, which are reported the incidence ranged 20% to 65%. This is also one of the reasons why it can cause significant mortality. Molecular targeted therapy plays a major role in the management of brain metastases in lung cancer. Targeted agents have become the novel methods for the treatment of lung cancer with brain metastases beyond the whole brain radiation therapy, stereotactic radiosurgery and chemotherapy. Recently, more and more studies and trials laid emphasis on the targeted agents for non-small cell lung cancer (NSCLC) brain metastases treatment. The key point is the efficacy and safety. In this paper, the targeted treatments of NSCLC brain metastases were summarized.
肺癌最常见的远处转移部位之一是脑部，肺癌脑转移的发生率为20%-65%，是脑转移性肿瘤中最常见的类型，同时也是肺癌死亡率高居不下的原因之一。分子靶向治疗已成为肺癌治疗的重要手段，分子靶向药物也成为继全脑放疗、立体定向放疗和化疗之后肺癌脑转移新的治疗方法。目前，对脑转移的非小细胞肺癌患者应用靶向药物治疗的研究也越来越多，其安全性和有效性是研究的重点。本文就靶向药物治疗非小细胞肺癌脑转移的研究进展做一综述。